Association between Insulin Resistance and Breast Carcinoma: A Systematic Review and Meta-Analysis
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Hernández, Adrian V.Guarnizo, Mirella
Miranda, Yony
Pasupuleti, Vinay
Deshpande, Abhishek
Paico, Socorro
Lenti, Hosten
Ganoza, Silvia
Montalvo, Laritza
Thota, Priyaleela
Lazaro, Herbert
Issue Date
2014-06-09
Metadata
Show full item recordCitation
PLoS ONE 9(6): e99317Publisher
Public Library of Science (PLoS)Journal
PLoS ONEDOI
10.1371/journal.pone.0099317Abstract
Objective: This study was undertaken to evaluate the association between components defining insulin resistance and breast cancer in women. Study Design: We conducted a systematic review of four databases (PubMed-Medline, EMBASE, Web of Science, and Scopus) for observational studies evaluating components defining insulin resistance in women with and without breast cancer. A meta-analysis of the association between insulin resistance components and breast cancer was performed using random effects models. Results: Twenty-two studies (n = 33,405) were selected. Fasting insulin levels were not different between women with and without breast cancer (standardized mean difference, SMD 20.03, 95%CI 20.32 to 0.27; p = 0.9). Similarly, non-fasting/ fasting C-peptide levels were not different between the two groups (mean difference, MD 0.07, 20.21 to 0.34; p = 0.6). Using individual odds ratios (ORs) adjusted at least for age, there was no higher risk of breast cancer when upper quartiles were compared with the lowest quartile (Q1) of fasting insulin levels (OR Q2 vs. Q1 0.96, 0.71 to 1.28; OR Q3 vs. Q1 1.22, 0.91 to 1.64; OR Q4 vs. Q1 0.98, 0.70 to 1.38). Likewise, there were no differences for quartiles of non-fasting/fasting C-peptide levels (OR Q2 vs. Q1 1.12, 0.91 to 1.37; OR Q3 vs. Q1 1.20, 0.91 to 1.59; OR Q4 vs. Q1 1.40, 1.03 to 1.92). Homeostatic model assessment (HOMAIR) levels in breast cancer patients were significantly higher than in people without breast cancer (MD 0.22, 0.13 to 0.31, p, 0.00001). Conclusions: Higher levels of fasting insulin or non-fasting/fasting C-peptide are not associated with breast cancer in women. HOMA-IR levels are slightly higher in women with breast cancer.Type
info:eu-repo/semantics/articleRights
info:eu-repo/semantics/openAccessLanguage
engDescription
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.EISSN
1932-6203Sponsors
This study was funded by the Instituto Me´dico de la Mujer, Lima, Peru. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.ae974a485f413a2113503eed53cd6c53
10.1371/journal.pone.0099317
Scopus Count
Collections